Navigation Links
Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
Date:5/9/2011

SAN DIEGO, May 9, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the first quarter of 2011.  For the three months ended March 31, 2011, Orexigen reported a net loss of $11.6 million, or $0.24 per share, as compared to a net loss of $14.1 million, or $0.30 per share, for the first quarter of 2010.  As of March 31, 2011, Orexigen had $39.6 million in cash and cash equivalents and an additional $36.9 million in marketable securities, for a total of approximately $76.6 million.

"Over the last several months, together with our partner, Takeda, and our external advisors, we have been preparing for a meeting with FDA to discuss a viable path forward for Contrave®," said Michael Narachi, president and CEO of Orexigen. "We have submitted to the Agency a specific, innovative, and robust proposal to assess cardiovascular risk and have confirmed a meeting with the Agency later this quarter to discuss our proposal."

Total operating expenses for the first quarter of 2011 were $13.3 million compared to $14.0 million for the first quarter of 2010. This decrease in operating expenses primarily reflects a decrease in research and development expenses of $1.4 million principally related to the reduction in costs incurred in connection with the preparation for our NDA filing for Contrave in the first quarter of 2011 as compared to same period in 2010. This overall decrease was partially offset by an increase in general and administrative expenses principally related to one-time corporate realignment costs.

Conference Call Today at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) The Orexigen management team will host a teleconference and webcast to discuss the first quarter 2011 financial results and recent business highlights. The l
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
2. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
3. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
4. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
5. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
6. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
7. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
8. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
9. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
10. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
11. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... Fla. , May 18, 2013 Although ... and are considered the most sensitive method for detecting ... effective in preventing cancer cases 3 . EndoChoice ® ... new Fuse™ system significantly improves the accuracy of this ... by colonoscopists. EndoChoice will be discussing these clinical trial ...
(Date:5/18/2013)... May 18, 2013 The Open Paradigm ... Occupy Psychiatry , and leading organizations ... announces a social media campaign showcasing video testimonials ... model, which focuses on pathology and illness rather ... the American Psychiatric Association,s (APA) rollout of its ...
(Date:5/18/2013)... 18, 2013 Faruqi & Faruqi, LLP, ... potential securities fraud at AVEO Pharmaceuticals, Inc. ("AVEO" ... http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation ... violated federal securities laws by issuing materially false ... drug trials for Tivopath (tivozanib) (titled "TIVO-1").  Specifically, ...
Breaking Medicine Technology:New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
... , July 19, 2010 Today, Novo Nordisk announced the,landmark recruitment of ... effects of modern insulins in,the management of type 2 diabetes.[1] , ... Spanning 28 countries across 4 continents and involving ... therapy. , , , ...
... Focused Ultrasound Surgery Foundation has announced that eight leading manufacturers are ... Focused Ultrasound, scheduled for October 17 through 20 near ... , , ... edge preclinical, translational and clinical research related to one of today,s ...
Cached Medicine Technology:World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 2World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 3MR-Guided Focused Ultrasound Symposium Announces Sponsors 2MR-Guided Focused Ultrasound Symposium Announces Sponsors 3
(Date:5/18/2013)... FRIDAY, May 17 (HealthDay News) -- As the American ... considered the "bible" of modern psychiatry this weekend, the ... unprecedented, the amount of commentary and debate and criticism," ... Association (APA). "It,s been an interesting phenomenon, but the ... it and then make your own determination of how ...
(Date:5/18/2013)... May 18 (HealthDay News) -- Children who swallow high-powered ... remove the objects, according to a new study. ... in New Orleans, found that more than 79 percent ... either surgery or an endoscopic procedure, in which a ... tract. Only 21 percent of these cases can be ...
(Date:5/18/2013)... News) -- Just a few extra cups of coffee ... autoimmune liver disease known as primary sclerosing cholangitis (PSC), ... Clinic in Rochester, Minn., found that drinking coffee was ... which can lead to cirrhosis of the liver, liver ... prove a cause-and-effect relationship. "While rare, PSC ...
(Date:5/18/2013)... 18, 2013 MOOSGO.COM published an original art ... book features a group of artists who share their creations ... illustrations and paintings. Exclusively for iPad . , ... songs and videos that reflect the signature idiosyncrasy and passion ... the Apple iBook Store and it includes a free ...
(Date:5/18/2013)... FL (May 18, 2013) The use of ... a colonoscopy, according to new research presented today ... which begins days in advance of the procedure, ... medication to be taken at strict intervals. The ... doctors to see cancer and precancerous polyps in ...
Breaking Medicine News(10 mins):Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 2Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 4Health News:Swallowing Magnets Can Be Fatal for Children 2Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2Health News:New Art Book for iPad: Tango Art 2Health News:New smartphone application improves colonoscopy preparation 2
... the first time, there is reason to believe that a ... -- which triggers growth of new blood vessels in hearts ... viable new option for thousands of patients suffering with heart ... range from drugs to surgical procedures that open blocked arteries ...
... doctors has found that aspirin works just as well as ... suspected that Warfarin was more effective but that aspirin was ... are equals in both respects. ,Both drugs slow ... the final stages of the most common type of stroke ...
... retrovirus that binds to receptors found on membranes of immune ... is internalized, copied into DNA, then migrates into the nucleus ... In many cases, the inserted viral genes remain dormant, sometimes ... Acquired Immune Deficiency Syndrome is a collection of 26 clinical ...
... implants in a woman's uterus, the more likely she is ... the latest New England Journal of Medicine details the most ... of pregnancy - influences its success or failure. ,Fertilised ... anywhere from six to 12 days after ovulation, the researchers ...
... children into learning too much too soon is more ... nursery experts. This setting of targets for three to ... as tantrums and bed-wetting, rather than achieve accelerated learning, ... are often intimidated by an early start to their ...
... asthma risks,say the researchers.Traditional student digs with mouldy and ... researchers. ,A study of over 20,000 Finnish students found ... risk of asthma, but left residents with a greater ... in damp houses were found to need more antibiotics ...
Cached Medicine News:Health News:More about HIV 2Health News:More about HIV 3
... Captia™ Varicella- Zoster Virus (VZV) IgG Enzyme- ... the detection and quantitative determination of IgG ... serum specimens may be used for the ... and convalescent, may be used to demonstrate ...
... Varicella-Zoster Virus (VZV) IgG Enzyme-Linked Immunosorbent ... and quantitative determination of IgG antibody to ... specimens may be used for the determination ... convalescent, may be used to demonstrate seroconversion ...
Inquire...
... Trinity Biotech Captia™ Mumps IgG Enzyme-linked Immunosorbent ... and quantitative determination of IgG antibody to ... specimens may be used for the determination ... convalescent, may be used to demonstrate seroconversion ...
Medicine Products: